PRESS-RELEASE filed Jul 23, 2026 at 06:00 ET
West Pharmaceutical reported Q2 2026 net sales of $872.3M (+13.8% YoY) and diluted EPS of $2.15 (+18.1% YoY), beating consensus estimates of $840M and $2.08. The company raised full-year 2026 adjusted-diluted EPS guidance to $8.85-$9.05 (from $8.40-$8.75) and net sales guidance to $3.345B-$3.380B, driven by strong HVP Components (+19.4%) and Biologics (+30.3%) growth. The beat and raised guidance signal accelerating demand for injectable solutions, particularly in GLP-1 and biologics, making this a clear positive catalyst for the stock.